Clinical Trial Update: GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update covers GH55 in Phase 1/2 for advanced solid tumors with MAPK pathway mutations, focusing on safety and early results; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• GH55

Snippet

Sponsor: Suzhou Genhouse Bio Co., Ltd. | Conditions: Advanced Solid Tumors With MAPK Signal Pathway Mutations | Phase 1, Phase 2 | Status: RECRUITING